Trial Profile
Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma; Eosinophilia
- Focus Therapeutic Use
- 15 Sep 2017 Status changed from recruiting to completed, based on the results published in the American Journal of Respiratory and Critical Care Medicine.
- 15 Sep 2017 Primary endpoint (Blood eosinophil absolute number) has been met, according to the results published in the American Journal of Respiratory and Critical Care Medicine.
- 15 Sep 2017 Primary endpoint (Sputum eosinophil percentage) has been met, according to the results published in the American Journal of Respiratory and Critical Care Medicine.